January 11, 2026 | InterContinental San Francisco
In a world where biotech innovation thrives on collaboration, Medicilon as the Featured Sponsor for the ACCESS ASIA BD Forum @ JPM 2026.
Our Mission: Your Partner from Concept to IND
As a global leader in integrated preclinical research services, Medicilon has long been the bridge between discovery and IND, supporting innovators from concept to clinical readiness. We provide seamless, world-class R&D services designed to accelerate your journey from early discovery to IND submission.
Who We Are: Two Decades of Empowering Innovation
From its inception in 2004, Shanghai Medicilon Inc. has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. Medicilon has built an integrated one-stop R&D platform covering drug discovery, CMC and preclinical studies, and has established service platforms in cutting-edge fields such as ADC, nucleic acids, peptides, CGT, PROTAC, and antibodies. Medicilon has established a quality system in compliance with international standards and has obtained GLP certifications from China’s NMPA, the US FDA, the EU OECD, and Japan’s PMDA, as well as AAALAC accreditation. Currently, Medicilon has nearly 80,000 square meters of R&D laboratories.
Medicilon Boston, part of Medicilon’s global dual-site operations (Boston, USA and Shanghai, China), offers non-GLP validated assay development with seamless workflow transfer to GLP execution in Shanghai, ensuring continuity from early discovery through IND-enabling studies. Medicilon Boston provides local accessibility with global expertise.
By the end of June 2025, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 588 new drugs and generic drug projects that have been approved for clinical trials with IND applications.
Why We Support ACCESS ASIA: A Shared Vision – Collaboration Beyond Borders
We integrated model empowers biotech firms — especially early-stage innovators — to achieve IND milestones globally, aligning perfectly with ACCESS ASIA’s mission to connect Asian innovation with global opportunity.
ACCESS ASIA BD Forum @ JPM 2026 brings together Asia’s leading biotech companies, global pharma executives, and VC/PE investors for a full day of keynotes, corporate presentations, and 1-on-1 partnering at the InterContinental San Francisco.
Medicilon’s sponsorship underscores the importance of partnership — not only between science and business but between regions and ecosystems shaping the future of healthcare.
A Message of Partnership
“Medicilon’s support highlights the growing strength of Asia’s biotech sector and its global impact. Together, we’re building a platform where innovation meets collaboration — and ideas turn into breakthroughs.”
Join Us in San Francisco
January 11, 2026 | InterContinental San Francisco
Scan QR code to register
